Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Use of an Analog Scale in the Treatment of Patients With Bipolar Disorder to Optimize Assessment and Clinical Outcome


Journal of Psychiatric Practice®: January 2017 - Volume 23 - Issue 1 - p 44–48
doi: 10.1097/PRA.0000000000000207

This column explains how a clinician can use an analog scale for patients with bipolar disorder: (1) to elucidate the course of the illness in a specific patient and (2) to assess response to treatment. This scale complements other standardized rating scales, such as the Young Mania Rating Scale, because its anchors are tailored to each specific patient in terms of the worst depressive or hypomanic/manic episode (ie, a −10 or +10, respectively) the person has ever experienced. The scale also allows clinicians to track how the individual patient’s episodes have responded to treatment in the past, including whether the patient ever has achieved a full remission (ie, score of 0) following the initial onset of the disorder. The scale can then be used to assess how the patient in an acute or chronic active episode responds to new treatment, whether somatic and/or psychotherapeutic, and how that compares with historical responses to previous treatments. Going forward, the scale can be used to assess the course of the patient’s illness (eg, episodic with full recovery or chronic with more severe episodes and increasing residual symptoms). Through use of this analog scale, the patient also develops a better understanding of his or her illness, including how episodes develop and resolve and whether there are factors (eg, interpersonal relationships, inflammatory processes, substance use) that either aggravate and/or are aggravated by the disorder. This simple scale thus fulfills many purposes including history gathering, monitoring the usefulness of different treatment interventions, and patient education.

PRESKORN: University of Kansas School of Medicine-Wichita, Wichita, KS

S.H.P. has worked with over 130 pharmaceutical companies in the United States and throughout the world. Over the past year, he has received grants/research support from or has served as a consultant, on the advisory board, or on the speaker’s bureau for Acadia, Alkermes, Assurex Health (developer and marketer of the GeneSight test), BioXcel, Food and Drug Administration, Eisai, Forum, Janssen, National Institute of Mental Health, Merck, Naurex/Aptinyx, Novaritis, Rugen Holdings, The Stanley Medical Research Institute, Sunovion, and Vanda.

Please send correspondence to: Sheldon H. Preskorn, MD, University of Kansas Medical Center, 1010 N. Kansas, Wichita, KS 67217.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.